In 40 seconds
After two decades of clinical research, high-intensity repetitive transcranial magnetic stimulation (rTMS) — paired with cognitive training — shows a small-to-moderate cognitive benefit in mild Alzheimer's disease and mild cognitive impairment across 17+ randomised trials and several meta-analyses [1][2][6]. The strongest single-trial signal is Koch's 2022 precuneus study in Brain [3], extended to 52 weeks in 2025 [4]. A large 2024 multisite trial without cognitive training was null [5]. Low-intensity consumer PEMF — the mats and home rings sold for general wellness in the UK — has no completed sham-controlled human RCT in any dementia. NICE NG97 (2018) explicitly recommends against transcranial magnetic stimulation for Alzheimer's outside a clinical trial. The UK Advertising Standards Authority upheld a complaint against advertising rTMS as an Alzheimer's treatment in 2018. The honest UK answer for families: probably not a treatment in 2026, but a credible adjunct research direction — and a legitimate wellness option for the carer's own stress, sleep and pain.
Quick facts
- Best-supported intervention: rTMS + cognitive training, multi-site, 5 sessions/week × 6 weeks (NeuroAD-style)
- Strongest single trial: Koch 2022 precuneus rTMS (n=50, Brain) — CDR-SB stable at 24 weeks; sustained to 52 weeks
- NICE position (NG97, 2018): Do NOT offer rTMS for Alzheimer's outside a clinical trial
- FDA position (March 2019): 14-0 panel vote against NeuroAD de novo clearance for Alzheimer's
- ASA position (March 2018): Complaint upheld against advertising rTMS-based treatment for Alzheimer's in the UK
- Low-intensity consumer PEMF in dementia: No completed sham-controlled human RCT
- Absolute contraindications: Pacemaker, ICD, cochlear implant, deep brain stimulator
- NHS England: rTMS not nationally commissioned for dementia
- Legitimate carer use: PEMF for the carer's own stress, sleep and chronic pain — evidence-supported wellness
The critical distinction: rTMS vs PEMF vs TEMT
Most online articles blur three very different things into one word. The page you're reading separates them, because the regulatory status, the evidence base, and the safety profile are not the same.
Repetitive transcranial magnetic stimulation (rTMS)
Brief, high-intensity magnetic pulses (around 1–2 Tesla at the coil) delivered by a clinical device, by a trained operator, in a regulated setting. Directly stimulates cortical neurons. NICE-approved in the UK for treatment-resistant depression; not approved for dementia. This is what the published Alzheimer's trials use.
Low-intensity consumer PEMF
Weak pulsed magnetic fields (typically microtesla to a few millitesla) from a mat, ring or pad sold for home wellness use. Mechanisms overlap with rTMS at the cellular level, but the clinical evidence base in dementia is preclinical and pilot-stage. MHRA classifies these as general wellness or general-purpose medical devices — not as dementia treatments.
Transcranial electromagnetic treatment (TEMT)
918 MHz radiofrequency electromagnetic field — closer to a low-power mobile-phone-band emission than to either rTMS or low-frequency PEMF. Studied in transgenic mice (Arendash 2010) and a single open-label pilot of 8 patients (Arendash 2019) with major commercial conflicts of interest. Not the same modality as the consumer PEMF mats sold in the UK.
When a sales page says "PEMF reverses Alzheimer's" and points to a study, the first question is: which one of these three did the study use? Almost always the answer is rTMS (clinical) or TEMT (a specific 918 MHz device), neither of which is the consumer PEMF mat being sold.
Evidence at a glance — landmark trials
The table below summarises the 17 most-cited primary trials and reviews in the field, ordered by year. Negative trials are included on purpose — a balanced evidence picture is the only one worth trusting.
| Study | Year | Population / n | Design | Intervention | Key result | Source |
|---|---|---|---|---|---|---|
| Cotelli et al. | 2008 | Mild & moderate-severe AD / n=24 | Sham-controlled cross-over | 20 Hz rTMS, bilateral DLPFC | Improved action-naming in moderate-severe AD; first language signal | PMID 18717730 |
| Cotelli et al. | 2011 | Mild–moderate AD / n=10 | RCT, 2 vs 4 weeks active | 20 Hz rTMS, left DLPFC, 5d/wk | Sentence comprehension improved; gains persisted to 8 weeks | PMID 20574108 |
| Rabey et al. | 2013 | Mild–moderate AD / n=15 | RCT, sham-controlled (NeuroAD pilot) | 10 Hz rTMS to 6 sites + cognitive training, 6 wk | ADAS-cog 3.76 points better than sham at 6 wk (p=0.03) | PMID 23151875 |
| Wu et al. | 2015 | Moderate AD / n=54 | Open-label vs TAU | 20 Hz rTMS, left DLPFC, 4 wk | Cognition and behavioural symptoms improved at 6 wk; persisted to 3 mo | PMC5464918 |
| Iaccarino et al. | 2016 | 5xFAD mice (preclinical) | Optogenetic + sensory 40 Hz | 40 Hz gamma entrainment | Reduced amyloid plaque load; activated microglia. Sensory entrainment, not PEMF. | Nature |
| Capelli et al. | 2017 | Aβ-stressed cell culture | In vitro | Low-freq PEMF, 75 Hz, 1.3 ms pulse | Modulated AD-related miRNAs; reduced BACE1 expression | PMC5434238 |
| Arendash et al. | 2019 | Mild–moderate AD / n=8 | Open-label pilot, no sham | TEMT 918 MHz, 2 × 1 hr/day × 2 mo | All 7 completers improved ADAS-cog ~4 pts; major commercial COI | JAD |
| Sabbagh et al. | 2020 | Mild–moderate AD / n=131 | Multicentre RCT, sham-controlled | 10 Hz rTMS to 6 sites + cognitive training | Whole-cohort primary endpoint MISSED. Mild-AD subgroup: ADAS-cog +1.93 vs sham at 12 wk (p=0.01) | PMID 31879215 |
| Bagattini et al. | 2020 | Moderate AD / n=30 | Pilot RCT, sham-controlled | H-coil deep TMS, 10 Hz, 20 sessions | ADAS-cog improved vs sham at end of treatment | PMID 33679572 |
| Chou et al. | 2020 | MCI / 12 RCTs / n=329 | Meta-analysis | High-freq, multi-site rTMS, ≥10 sessions | Improved general cognition and memory in MCI | PMC8576192 |
| Lefaucheur et al. | 2020 | Across indications | European guideline update | n/a — recommendation only | Level B "probable efficacy" for high-freq DLPFC rTMS + cognitive training in mild AD | PMID 31901449 |
| Cao & Arendash | 2022 | 5 of original 8 AD patients | Open-label extension, no sham | TEMT 918 MHz, 1 hr/day × 30 mo | No cognitive decline in completers over 2.5 yr; commercial COI | PMC9416517 |
| Wang et al. | 2022 | AD / 17 RCTs / n=437 | Meta-analysis | rTMS vs sham | Improved MMSE and ADAS-cog (SMD ~0.7); strongest with high-freq + training | DOI |
| Koch et al. | 2022 | Mild–moderate AD / n=50 | Phase 2 RCT, sham-controlled, 24 wk | 20 Hz rTMS to precuneus | CDR-SB stable in active arm while sham declined — strongest single-trial signal | Brain |
| Yang et al. | 2023 | AD / 10 RCTs / n=408 | Meta-analysis | rTMS + cog. training vs training alone | SMD 0.66 (95% CI 0.30–1.02); persists 1–3 mo | DOI |
| Chu et al. | 2024 | MCI / AD / 143 studies / n≈5,800 | Systematic review | — | Statistically significant cognitive improvement; low-to-moderate GRADE certainty | PMC11306417 |
| Wei et al. | 2024 | Mild–moderate AD, multisite | RCT, sham-controlled | Stand-alone rTMS DLPFC (no cog. training) | NULL — no superiority over sham. Important negative trial. | PMC10937236 |
| Koch et al. | 2025 | n=48 from 2022 trial | 52-wk extension | Precuneus rTMS, weekly maintenance | CDR-SB benefit sustained at 1 year | ARTh |
The honest read on this table
Almost every positive trial used rTMS — high-intensity, clinical, paired with cognitive training. The strongest single signal (Koch 2022) used a non-obvious target (precuneus, not DLPFC). The largest 2024 trial without cognitive training was null. None of the trials in this table used the kind of low-intensity PEMF mat sold to UK consumers for home use. Anyone telling you a £2,000 PEMF mat is "what the studies show works" is conflating modalities.
Sub-type breakdown — what the evidence says by dementia type
Alzheimer's disease
Best-studied. Most-supported intervention is rTMS to multi-site cortex (DLPFC, language areas, parietal) at 10–20 Hz, paired with computerised cognitive training, 5 sessions per week for 6 weeks. Effect sizes in the meta-analyses are SMD ~0.5–0.7 on cognitive measures, translating roughly to a 1.5–3 point ADAS-cog improvement at the cohort level. Effects are real but modest, certainty is low-to-moderate, and individual responses vary widely. Precuneus stimulation (Koch 2022/2025) is the most promising single target. Stand-alone DLPFC rTMS without cognitive training was null in Wei 2024 — protocol matters more than device brand. For low-intensity consumer PEMF in Alzheimer's there is no completed sham-controlled human RCT. Read the Alzheimer's-specific page →
Vascular dementia
Very limited evidence. No phase-3 RCT of rTMS or PEMF specifically in vascular dementia. Most trials either exclude VaD or pool it with mixed dementia. Lefaucheur's 2020 European guideline makes no specific recommendation. Small case series suggest possible cognitive benefit; insufficient for clinical claims. Vascular risk-factor optimisation (blood pressure, lipids, atrial fibrillation, diabetes) remains the only intervention with disease-modifying evidence in VaD. Read the vascular dementia page →
Lewy body dementia (DLB)
Effectively no RCT data in DLB. Theoretical caution: people with DLB may have higher seizure susceptibility and visual-cortex hyperexcitability. The Lefaucheur 2020 guideline issues no recommendation. Critical safety point: some DLB patients have deep brain stimulators implanted for parkinsonian symptoms — rTMS is contraindicated with implanted DBS systems per Boston Scientific and Abbott neuromodulation labelling. PEMF over the head should be discussed with the neurologist supervising any DBS. Read the Lewy body dementia page →
Frontotemporal dementia (FTD)
Pilot work only. A current ClinicalTrials.gov registration (NCT07316413) is recruiting for a two-phase rTMS-in-FTD trial. Evidence base is much thinner than Alzheimer's. Behavioural-variant FTD raises additional capacity-to-consent challenges because impulsivity and disinhibition appear early.
Mixed dementia
Not separately studied. By post-mortem standards, real-world Alzheimer's trial populations contain mixed pathology. Outcomes are likely to track the Alzheimer's evidence above, with the caveat that effect sizes may be smaller because mixed dementia tends to be more advanced at diagnosis.
Mild cognitive impairment (MCI)
The most-supported indication outside of Alzheimer's itself. Chou 2020 meta-analysis (12 RCTs, n=329) found high-frequency, multi-site rTMS with 10+ sessions improved general cognition and memory in MCI. The effect on executive function is less consistent. Newer intermittent theta-burst (iTBS) protocols are being trialled at NIH-funded sites. NICE makes no specific recommendation. The case for early-stage intervention before full Alzheimer's diagnosis is intellectually attractive but unproven at trial level.
Sundowning, agitation and BPSD
Limited but encouraging. Wu 2015 (n=54, moderate AD) showed reduction in BEHAVE-AD scores with DLPFC rTMS. A 2023 systematic review of TMS for behavioural and psychological symptoms of dementia found a positive direction-of-effect signal that remains preliminary. There is no completed PEMF RCT specifically for sundowning. Non-pharmacological alternatives with stronger evidence include light therapy, structured activity programmes, and group cognitive stimulation therapy (the only intervention NICE NG97 endorses for cognition and wellbeing in mild-to-moderate dementia). Read the sundowning page → · Read the agitation page →
Sleep disturbance
No completed dementia-specific PEMF or rTMS sleep RCT. General PEMF sleep trials exist but samples are small and most are brand-funded. NICE recommends light therapy and melatonin where appropriate for dementia sleep. Do not extrapolate general PEMF sleep evidence to people with dementia — the comorbidities and medication interactions are different.
Carer wellbeing — the legitimate PEMF use case
This is where PEMF in a dementia household actually has evidence. Carers experience chronic stress, sleep disruption and musculoskeletal pain. PEMF has acceptable trial evidence for stress-related symptoms (Bredahl et al. 2017, n=96), chronic low back pain, and general sleep quality. A carer using a PEMF mat for their own back pain or insomnia is a reasonable wellness choice. This is not, however, treatment for the person being cared for — frame it correctly when you discuss it. Read the sleep page → · Read the back pain page →
How magnetic stimulation might affect dementia — proposed mechanisms
Several biological mechanisms have been proposed and tested in the laboratory. The cellular and circuit-level effects are real. Whether they translate to clinically meaningful disease modification in humans is still being established.
| Proposed mechanism | What it means | Citation |
|---|---|---|
| Cortical excitability modulation | rTMS at >5 Hz raises cortical excitability; ≤1 Hz lowers it. Even low-intensity PEMF (75 Hz, 1.8 mT) selectively increases intracortical facilitation. | Capone 2009 |
| Neuroplasticity / LTP-like effects | Repeated stimulation induces long-term potentiation-like synaptic changes, the cellular basis of learning. | Antonioni 2025 |
| BDNF upregulation | rTMS increases brain-derived neurotrophic factor and TrkB receptor responsiveness in animal models. | 3xTg-AD mouse |
| Cerebral blood flow | High-frequency DLPFC rTMS plus cognitive training increases regional cerebral blood flow in AD. | Front Neurol 2023 |
| Default-mode network connectivity | Precuneus stimulation restores effective connectivity in the default-mode network — a circuit that fails early in Alzheimer's. | Koch 2022 |
| Cytokine rebalancing | TEMT shifts pro-inflammatory cytokines toward anti-inflammatory profile in AD patients. | Arendash 2022 |
| Microglial polarisation | PEMF shifts microglia from M1 (pro-inflammatory) toward M2 (resolving) phenotype in culture. | 2024 in vitro |
| miRNA / BACE1 modulation | Low-frequency PEMF modulates AD-related miRNAs and reduces BACE1 in cell culture. | Capelli 2017 |
| Mitochondrial protection | PEMF protects neurons from amyloid-β-induced mitochondrial damage and restores CREB/BDNF signalling. | PMC11641689 |
| Glymphatic / amyloid clearance | 40 Hz gamma sensory entrainment increases glymphatic clearance via VIP+ interneurons in mice. (Sensory, not PEMF — often cited in PEMF marketing.) | Iaccarino 2016 |
None of the mechanisms above prove clinical efficacy. They establish biological plausibility and explain why the trial signals exist where they do. The Wei 2024 null trial is a reminder that plausibility does not equal effect.
UK regulatory position — NICE, MHRA, the Alzheimer's Society and the ASA
This is the section almost no commercial PEMF page in the UK puts at the top. It should be at the top, because it tells you what claims a UK seller can legally make.
MHRA (Medicines and Healthcare products Regulatory Agency) classifies medical devices under UK Medical Devices Regulations 2002 (as amended). PEMF wellness devices marketed in the UK are typically Class IIa, cleared for general claims (musculoskeletal, wellness). They are not MHRA-cleared as treatments for Alzheimer's, dementia, or any cognitive disorder. Clinical rTMS devices (Magstim, MagVenture, Brainsway H-coil, Neuronetics NeuroStar) are Class IIb with specific clinical indications — depression and OCD, not dementia.
Alzheimer's Society UK does not endorse rTMS or PEMF as a treatment for dementia. The Society publicly supported the 2018 ASA complaint against Neuronix, with then-policy chief Dr Doug Brown stating the supporting evidence came from "preliminary studies which are not the same as robust clinical trials."
Advertising Standards Authority — 21 March 2018 ruling against Neuronix Ltd. A magazine advertisement called NeuroAD "a new treatment for Alzheimer's disease" and claimed gains in memory, mood, language, attention, and daily function. The ASA upheld the complaint: "the current evidence base was insufficient to support the claims" and the advert must not appear in its current form again. This is the single most-cited UK regulatory precedent for rTMS-and-Alzheimer's advertising. It bounds what any commercial PEMF or rTMS clinic in the UK can legally say in 2026.
NHS England commissions rTMS only for treatment-resistant depression in specific trusts (UCLH, Somerset NHSFT, Hampshire & IoW NHSFT, East London NHSFT). It is not nationally commissioned for dementia. UK patients seeking rTMS for dementia access it only through clinical trial enrolment or through private clinics — which are themselves bound by ASA standards.
FDA — for contrast. On 21 March 2019 the FDA Neurological Devices Panel voted 14-0 against granting de novo clearance to Neuronix NeuroAD for Alzheimer's. Safety standards were met; efficacy was not demonstrated to the panel's satisfaction. The device remains marketed in the EU, Australia and Israel but is not cleared in the US for AD.
Safety and contraindications specific to dementia
Standard PEMF and rTMS contraindications apply (pacemakers, ICDs, cochlear implants, deep brain stimulators, spinal cord stimulators, insulin pumps, active malignancy without oncologist clearance). A few additional considerations matter specifically in dementia.
Deep brain stimulators (DBS)
Some Parkinson's-dementia overlap patients have DBS. rTMS is contraindicated with implanted DBS per Boston Scientific and Abbott neuromodulation labelling. PEMF over the head should be discussed with the neurologist who manages the DBS.
Seizure threshold
rTMS-induced seizure risk is around 0.1% (~16 per 10,000), higher with high-frequency protocols. Dementia is a relative risk factor, especially when patients are on bupropion, lithium, clozapine, tramadol or some antipsychotics used in BPSD.
Capacity to consent
The Mental Capacity Act 2005 applies. Moderate-to-severe dementia patients may lack capacity. A best-interests decision involving family, LPA-holder and clinical team is required for any unproven treatment.
Falls risk
Some home PEMF protocols involve a mat on the floor. For an unsteady or confused person this is an additional trip hazard. Practical risk assessment is sensible.
Financial exploitation
Dementia patients are a recognised vulnerable population for health-claim marketing. The 2018 ASA ruling against Neuronix shows the UK regulator actively enforces — but reactively. Families should ask for the actual claim in writing before paying.
Drug interactions to flag
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), memantine, and anti-amyloid antibodies (lecanemab, donanemab) where prescribed should never be stopped to "try PEMF instead." Decisions to add non-pharmacological adjuncts should be reviewed with the prescribing memory clinic.
Practical guidance for UK families
If you're reading this page because someone you love has been diagnosed with dementia, here is what the evidence in 2026 supports as a sensible sequence:
- Get the diagnosis confirmed and a treatment plan in place. Memory clinic, cholinesterase inhibitor or memantine where indicated, vascular risk-factor optimisation if any vascular component, and a referral to cognitive stimulation therapy (CST) — the only non-pharmacological intervention NICE NG97 specifically endorses for mild-to-moderate dementia.
- Treat reversible contributors aggressively. Sleep apnoea, depression, hearing loss, B12 deficiency, polypharmacy review. Each of these has stronger evidence for cognitive benefit than any current PEMF protocol.
- If clinical rTMS is being considered, look for a trial. ClinicalTrials.gov, the UK Dementia Research Institute, and major neurology centres in London, Cambridge and Manchester recruit for cognition-related trials. Asking your consultant for a trial referral is the safest route to evidence-based rTMS.
- For consumer PEMF, frame the use case honestly. The strongest evidence-based home use is for the carer's stress, sleep and chronic pain — not as a dementia treatment for the person being cared for. Anyone selling you a PEMF mat as a dementia cure is overpromising.
- Document the decision. Especially where the person with dementia lacks capacity, the best-interests process should be written down: who decided, on what evidence, with what review date.
- Re-review every 6 months. The evidence base is moving. The 2025 Koch 52-week extension and 2024 Wei null trial are both recent. A claim that was unsupported in 2024 may be supported in 2027 — or vice versa.
Contraindications — the full screen
Hard exclusions — do not have PEMF or rTMS if any apply:
- Pacemaker, implantable cardioverter-defibrillator (ICD), or any cardiac electronic device
- Cochlear implant or other implanted electronic hearing device
- Spinal cord stimulator, deep-brain stimulator (DBS), vagus nerve stimulator
- Intrathecal pump or implanted drug pump
- Insulin pump (continuous glucose monitors are usually fine — confirm with the clinic)
- Active infection at the treatment site
- Pregnancy — when treatment would be over the abdomen, lumbar spine, or pelvis
Discuss with the GP or specialist before booking if any apply:
- Active malignancy or recent cancer history — oncologist clearance required
- History of seizures, epilepsy, or recent head injury
- Antipsychotics, bupropion, lithium, clozapine, tramadol — seizure-threshold-lowering medications
- Anticoagulant therapy
- Moderate-to-severe dementia where capacity to consent is in doubt — best-interests decision required under the Mental Capacity Act 2005
- Recent neurosurgery within the last 14 days
Not contraindications — commonly misunderstood:
- Plates, rods, screws, and other passive metal orthopaedic hardware
- Dental implants and dental crowns
- Joint replacements (hip, knee, shoulder)
- Tattoos and piercings (jewellery should be removed for any rTMS session)
Specific to dementia: DBS, pacemaker, cochlear implant, seizure history, antipsychotics with low seizure threshold, capacity-to-consent under Mental Capacity Act 2005.
Frequently asked questions
Can PEMF therapy help with dementia?
There is no completed sham-controlled human trial showing low-intensity consumer PEMF stops, slows, or reverses any dementia. High-intensity clinical rTMS — paired with cognitive training — shows a small-to-moderate cognitive benefit in mild Alzheimer's and MCI across multiple meta-analyses. NICE recommends against rTMS for Alzheimer's outside a clinical trial.
Does PEMF help Alzheimer's disease?
Clinical rTMS combined with cognitive training has shown statistically significant cognitive improvement in mild Alzheimer's across the Wang 2022, Yang 2023 and Chu 2024 meta-analyses. Effects are modest and certainty is low-to-moderate. Consumer PEMF devices have no completed human RCT in Alzheimer's. The 2024 Wei trial of stand-alone rTMS without cognitive training was null — the protocol matters more than the device.
Is rTMS available on the NHS for dementia?
No. NHS England commissions rTMS only for treatment-resistant depression in specific trusts. It is not nationally commissioned for dementia. UK patients can access rTMS for dementia only through clinical trial enrolment or private clinics — which cannot legally claim dementia efficacy under ASA rules.
Can magnetic therapy reverse Alzheimer's?
No. Dementia is progressive. No published trial has shown reversal of Alzheimer's pathology with rTMS or PEMF in humans. Anti-amyloid antibodies (lecanemab, donanemab) reduce decline rate but do not reverse the disease either.
What is the best PEMF device for dementia?
No PEMF device is cleared by the MHRA in the UK, or by the FDA in the US, for the treatment of dementia. NeuroAD (Neuronix) is the most-studied rTMS-plus-cognitive-training combination — approved in the EU/Australia/Israel, refused FDA clearance for AD in 2019, and subject to a 2018 ASA ruling in the UK. Low-intensity home PEMF devices are sold as wellness products only.
Is PEMF safe for elderly people with dementia?
Low-intensity PEMF has a benign general safety profile. Dementia-specific risks include pacemaker / ICD / DBS interactions (absolute exclusions), seizure threshold concerns with rTMS when antipsychotics are involved, and capacity-to-consent issues under the Mental Capacity Act 2005. Screen with the GP first.
What's the difference between PEMF and rTMS?
rTMS uses brief, high-intensity magnetic pulses (around 1–2 Tesla at the coil) delivered by a clinical device under supervision. PEMF uses low-intensity magnetic fields (typically microtesla to a few millitesla) delivered by consumer mats, rings or pads. They are not interchangeable — evidence base, regulatory status, and use case are all different.
Has PEMF been proven to help dementia in clinical trials?
Clinical rTMS has been studied in over 140 trials with around 5,800 participants (Chu 2024). The collective signal is small-to-moderate cognitive benefit in mild Alzheimer's and MCI with low-to-moderate certainty. Low-intensity consumer PEMF has no completed sham-controlled human RCT in dementia.
What does the Alzheimer's Society say about PEMF and rTMS?
The Alzheimer's Society UK does not endorse rTMS or PEMF as treatments for dementia. The Society publicly supported the 2018 ASA upheld complaint against Neuronix, calling the supporting research "preliminary studies which are not the same as robust clinical trials."
Can you use PEMF if you have a pacemaker?
No. Pacemakers, ICDs, cochlear implants, DBS and spinal cord stimulators are absolute contraindications to PEMF and rTMS over the body or head.
Does PEMF help sundowning and dementia agitation?
Limited but encouraging rTMS evidence. Wu 2015 (n=54) showed reduced behavioural and psychological symptoms with DLPFC rTMS. A 2023 systematic review of TMS for BPSD found a positive direction-of-effect signal that remains preliminary. No completed PEMF RCT specifically for sundowning.
How often should a carer use a PEMF mat for themselves?
This is the most legitimate dementia-household use case. Carers face chronic stress, sleep disruption and musculoskeletal pain. Typical home protocols are 8–30 minutes once or twice daily. This is wellness for the carer — not treatment for the person being cared for.
Is PEMF a scam for dementia?
The biology is real — PEMF demonstrably affects cortical excitability, microglial polarisation and BDNF expression in laboratory settings. The clinical evidence for treating dementia with low-intensity consumer PEMF does not yet exist. Claims that home PEMF will slow or reverse dementia go beyond the evidence and may breach UK advertising standards.
Can PEMF help vascular dementia or only Alzheimer's?
Most research has been done in Alzheimer's. There are no phase-3 RCTs of rTMS or PEMF specifically in vascular dementia. Small case series suggest possible benefit but evidence is insufficient for clinical claims.
Are there any UK studies on PEMF for dementia?
No UK-led phase-3 trial of rTMS or PEMF for dementia is on the public registers as of May 2026. Most active trials are in Italy (Koch group, precuneus), the US, Israel and China.
How long does rTMS take to work for memory?
Protocols that showed benefit ran 5 sessions per week for 4–6 weeks, sometimes with weekly maintenance for several months (Koch 2022 ran 2 weeks daily plus 22 weeks weekly). Cognitive change is measured at 6–12 weeks. Effects are typically detected only at the cohort level — individual response is variable.
Is PEMF FDA-approved for Alzheimer's?
No. On 21 March 2019 the FDA Neurological Devices Panel voted 14-0 against granting de novo clearance to Neuronix NeuroAD for Alzheimer's disease.
Can PEMF help dementia sleep disturbance?
No completed dementia-specific PEMF or rTMS sleep RCT. General PEMF sleep trials are small and brand-funded. NICE guidance for dementia sleep recommends light therapy and melatonin where appropriate.
Can someone with dementia consent to PEMF or rTMS?
The Mental Capacity Act 2005 applies. Moderate-to-severe dementia patients may lack capacity. A best-interests decision involving family, LPA-holder, and clinical team is required for any unproven treatment.
What is the strongest single trial signal for rTMS in Alzheimer's?
As of May 2026, Koch et al. 2022 in Brain (n=50). 24 weeks of precuneus rTMS held CDR-SB stable in the active arm while sham deteriorated, and the 2025 52-week extension sustained the effect.
Related dementia pages on PEMF UK
Sources
- Cotelli M, et al. Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. Eur J Neurol, 2008. PMID 18717730
- Cotelli M, et al. Improved language performance in Alzheimer disease following brain stimulation. J Neurol Neurosurg Psychiatry, 2011. PMID 20574108
- Rabey JM, et al. rTMS combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease. J Neural Transm, 2013. PMID 23151875
- Wu Y, et al. Adjunctive high-frequency rTMS for BPSD in patients with Alzheimer's disease. Shanghai Arch Psychiatry, 2015. PMC5464918
- Iaccarino HF, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature, 2016. PMID 27929004
- Capelli E, et al. Low-frequency PEMF modulates miRNAs in an experimental cell model of Alzheimer's disease. J Healthc Eng, 2017. PMC5434238
- Arendash GW, et al. A clinical trial of transcranial electromagnetic treatment in Alzheimer's disease. J Alzheimers Dis, 2019. DOI 10.3233/JAD-190367
- Sabbagh M, et al. Effects of a combined TMS and cognitive training intervention in Alzheimer's disease. Alzheimer's & Dementia, 2020. PMID 31879215
- Bagattini C, et al. rTMS with H-coil in Alzheimer's disease: a double-blind, placebo-controlled pilot study. Front Neurol, 2020. PMID 33679572
- Chou YH, et al. Effects of rTMS in patients with mild cognitive impairment. Front Aging Neurosci, 2020. PMC8576192
- Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of rTMS: an update (2014–2018). Clin Neurophysiol, 2020. PMID 31901449
- Cao C, Arendash GW, et al. TEMT stops Alzheimer's cognitive decline over a 2½-year period. Medicines, 2022. PMC9416517
- Wang X, et al. Effects of rTMS treatment on global cognitive function in Alzheimer's disease. Front Aging Neurosci, 2022. DOI 10.3389/fnagi.2022.984708
- Koch G, et al. Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. Brain, 2022. DOI 10.1093/brain/awac285
- Yang Y, et al. Effects of rTMS combined with cognitive training on cognitive function in patients with Alzheimer's disease. Front Aging Neurosci, 2023. DOI 10.3389/fnagi.2023.1254523
- Chu C, et al. Efficacy and safety of TMS on cognition in MCI, AD, AD-related dementias, and other cognitive disorders: a systematic review and meta-analysis. Neurology, 2024. PMC11306417
- Wei N, et al. rTMS as a treatment for Alzheimer's disease: a randomized placebo-controlled double-blind clinical trial. Brain Stimulation, 2024. PMC10937236
- NICE. NG97 Dementia: assessment, management and support for people living with dementia and their carers. 2018, revised. nice.org.uk/guidance/ng97
- NICE. HTG396 / IPG542 Repetitive transcranial magnetic stimulation for depression. nice.org.uk/guidance/HTG396
- Advertising Standards Authority. ASA Ruling on Neuronix Ltd. (NeuroAD). 21 March 2018. asa.org.uk/rulings
- Alzheimer's Society UK. Complaint upheld against advertising of NeuroAD as an Alzheimer's disease treatment. alzheimers.org.uk/news
- NHS rTMS commissioning information: UCLH; Somerset NHSFT
- FDA Neurological Devices Panel briefing. Neuronix NeuroAD (DEN160053). 21 March 2019. FDA briefing document
- Koch G, et al. Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial. Alzheimer's Research & Therapy, 2025. DOI 10.1186/s13195-025-01709-7
- Capone F, et al. Does exposure to extremely low frequency magnetic fields produce functional changes in human brain? J Neural Transm, 2009. DOI 10.1007/s00702-009-0184-2
- Effect of low-frequency, low-energy PEMF in neuronal and microglial cells injured with amyloid-β. Int J Mol Sci, 2024. PMC11641689
Looking for a PEMF clinic in the UK?
We list every credible PEMF therapy provider in the UK so you can find one nearby. Please remember: no UK clinic can legally claim to treat dementia with PEMF or rTMS. Ask for the specific claim in writing before paying.